Research at a glance.
Two evidence clusters.
Pre-Clinical Research
In-vitro and animal research on gastric mucosal protection, diarrheal support, cholesterol reduction, collagenase inhibition and antioxidant activity.
Safety, Quality & Toxicology
Bacospore® 300B is released against defined heavy-metal, microbiological, GMO-free and BSE/TSE-free specifications.
Study index.
| Year | Study | Model | Key outcome |
|---|---|---|---|
| 2026 | Strain-Specific Modulation of Oxidative Stress, Carbohydrate Metabolism and Adipogenesis by Probiotic Bacillus spp. in 3T3-L1 Cells | 3T3-L1 cells, four Bacillus strains | Strongest antioxidant activity of the four strains; high cell viability. |
| 2026 · in press | Evaluation of Antidiarrheal, Antiulcer, Anti-Collagenase and Cholesterol-Lowering Activity of Heyndrickxia coagulans MTCC 25308 | Ethanol-ulcer & castor-oil diarrhoea in rats; in-vitro assays | 80.4% ulcer inhibition · 26.6% diarrhoea inhibition · 85.40% collagenase · 97.72% cholesterol reduction. |
How we label our evidence.
Because probiotic characteristics and effects can vary between strains, we clearly identify the exact strain evaluated in every study presented on this website. Research specific to Bacospore® includes laboratory, cellular, and animal studies. This distinction ensures that the evidence is presented transparently and that strain-specific findings are clearly separated from broader research on the species. The statements presented on this website have not been evaluated by the FDA or EFSA. Bacospore® is not intended to diagnose, treat, cure, or prevent any disease.
